Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease - Wikidata - awgldk - TriplyDB

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease

http://www.wikidata.org/entity/Q36604545

about

The generation and function of soluble apoE receptors in the CNS The genetic epidemiology of neurodegenerative disease.Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation Molecular interactions between apoE and ABCA1: impact on apoE lipidation Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease Reelin expression and glycosylation patterns are altered in Alzheimer's disease Apolipoprotein E and Alzheimer disease Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy Allosteric modulator Desformylflustrabromine relieves the inhibition of α2β2 and α4β2 nicotinic acetylcholine receptors by β-amyloid(1-42) peptide Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease Reelin signaling antagonizes beta-amyloid at the synapse Similar promotion of Abeta1-42 fibrillogenesis by native apolipoprotein E epsilon3 and epsilon4 isoforms Cardiovascular damage in Alzheimer disease: autopsy findings from the Bryan ADRC.Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores Advances in development of fluorescent probes for detecting amyloid-β aggregates Cerebrovascular disease in ageing and Alzheimer's disease Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease Successful therapies for Alzheimer's disease: why so many in animal models and none in humans?Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions Do Microglia Default on Network Maintenance in Alzheimer's Disease?Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease Neuroserpin binds Abeta and is a neuroprotective component of amyloid plaques in Alzheimer disease Reelin and apoE actions on signal transduction, synaptic function and memory formation Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-β in human Alzheimer brain ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis Apolipoprotein E expression is elevated by interleukin 1 and other interleukin 1-induced factors Extensive proteomic screening identifies the obesity-related NYGGF4 protein as a novel LRP1-interactor, showing reduced expression in early Alzheimer's disease PuF, an antimetastatic and developmental signaling protein, interacts with the Alzheimer's amyloid-β precursor protein via a tissue-specific proximal regulatory element (PRE)Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset Isoform-specific effects of apoE on neurite outgrowth in olfactory epithelium culture Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential PET amyloid-beta imaging in preclinical Alzheimer's disease Genomic variants, genes, and pathways of Alzheimer's disease: An overview.Cytoskeletal pathologies of Alzheimer disease

P2860

Q21202840-A4213EF2-5BE2-4343-991B-316FAA2DB68F Q22306301-67E3B37F-E118-447E-9120-69256CB23C06 Q24291128-F642D8FF-0031-4C72-B6F0-654A74CEE966 Q24306797-222A12AC-C34F-49A3-AE3C-D475E1E90BC5 Q24308731-D10F69C7-86DA-4AB7-B54F-2FC11D18BDB2 Q24541523-0B166940-7700-4350-B8DA-38EF8650CDC7 Q24563061-0DA88461-3434-4D4B-AE0C-D330CDA876BB Q24594531-7937778E-122B-4E05-8426-91D503B873FA Q24604376-36BD8A32-9799-4B30-8815-8AB8018DED26 Q24629740-81B232EB-7476-4012-978B-EA0A035AD756 Q24631387-21E37AEC-8FDA-4C9F-9515-CBE446DE42C1 Q24651028-F5BD0140-9D84-4F2F-BBA2-19C504E86426 Q24805441-6F64D465-7F30-46DE-B963-036018A5E192 Q24811731-EE67685A-93A3-40BD-B89A-D2BB7B76559C Q26738355-9F420F4E-E1B4-477E-BEA8-3DD050D44DB1 Q26753175-39F53026-9B05-499E-BBC6-A6DC0196CAAB Q26771852-A4CB3047-E302-41B7-BCE2-C1606E390A31 Q26858870-BA2F42D9-03B0-461E-8C15-6FF93D10AA20 Q26859305-63604455-3498-421C-A2C8-FDBDE564705F Q26864965-BB45697F-F816-4415-8F6D-95ABE9C94C9C Q28066112-5721E7C8-8CA5-4CEF-B3A1-0760C1A87908 Q28217153-8CC70908-C5D1-48C4-9ACC-5CB2A1E870A1 Q28245473-942F11E4-C8F1-4D3D-97D6-633FDFA43D47 Q28252760-2D50F12D-41C4-4D38-BD9B-08A457349AA4 Q28254650-FEF0CC71-474A-4FA3-8587-320E4380A886 Q28282855-CDE8DC04-C797-4525-8FCD-EE69139985CD Q28307028-D3D00755-07B5-4D9D-9B21-6DE6AE504F28 Q28477020-3A9EB7F8-2CC7-4449-BF40-886313144FA8 Q28504715-C5876B96-67A3-4D14-954B-FD53F736117C Q28576453-1805EC3A-B9D1-43BA-B50B-1FAFD5B89B64 Q28588684-038E5099-0BA7-4FFA-A8A9-0C2CEB38D7E7 Q28706304-FDD2B23C-CCF2-4303-8CAB-764E4C7A0A88 Q28730795-4D84D8AC-6591-4B97-BF26-FF3D845D635D Q28771485-6132E359-91C6-4211-93B1-B138E6B976A8 Q28775941-2171AB57-E3DA-4E57-BCE7-4DBD08F1A717 Q29547593-4CB0FDEA-E1FB-426D-9FF4-673BFE70D014 Q29994589-BA8F3FEC-02A2-42C6-8E50-F7BD3E596270 Q30040695-1F9EB990-C276-4B6A-AE2A-BF58805186E0 Q30240093-F78634A8-35F0-490D-AAEE-66224039D696 Q30435267-043603AE-137E-42DA-ADB2-BD6A52261745

P2860

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease

http://www.wikidata.org/entity/Q36604545

description

1993 nî lūn-bûn

@nan

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu

1993年论文

@zh

1993年论文

@zh-cn

name

Increased amyloid beta-peptide ...... n late-onset Alzheimer disease

@ast

Increased amyloid beta-peptide ...... n late-onset Alzheimer disease

@en

type

label

Increased amyloid beta-peptide ...... n late-onset Alzheimer disease

@ast

Increased amyloid beta-peptide ...... n late-onset Alzheimer disease

@en

prefLabel

Increased amyloid beta-peptide ...... n late-onset Alzheimer disease

@ast

Increased amyloid beta-peptide ...... n late-onset Alzheimer disease

@en

P1433

Q36604545-C7ED2DFF-D2CE-4513-B16F-683813CF5D35

P1476

Q36604545-1EA62548-373F-48EF-8366-53E29F3AC443

P2093

Q36604545-3A3EAB19-1516-4ADB-9762-147AE9BCFCEC

Q36604545-425BF315-209D-4311-9666-6C4A5C8EDB50

Q36604545-6D55412A-408C-469D-8155-7C5EC44DF4BE

Q36604545-74164334-2EDE-4958-B7E6-6E2928CD7300

Q36604545-8AECCE37-806E-43B8-AF25-9C301A1601A2

Q36604545-9C088DE1-E357-48F5-9B34-473D4A98A766

Q36604545-A9E5E7F4-3514-4C03-8AFA-8BF3569516FE

Q36604545-BF922518-051C-4E9E-84BA-A7D3E880CB55

Q36604545-C34D4417-C903-42E2-83D0-08A333CED78F

P2860

Q36604545-11EF3DC3-4A67-471A-86BB-0D6940144B84

Q36604545-157D41A6-05CB-4F49-8352-F6011BF34954

Q36604545-1657256E-6CDE-42B1-84AA-94D9B3666A4C

Q36604545-187B973F-23E4-43AC-A490-202D0E4A98FC

Q36604545-1A5A4142-9F6E-45AC-87BE-B876289F6203

Q36604545-1F03B317-A345-41E7-8779-A893BAE2779D

Q36604545-2442B3EC-BC52-4C68-B91F-121DA3D9EEDA

Q36604545-278CF4CA-E0C0-4B6D-83D0-E6D34B57788D

Q36604545-28AED3AD-8956-4056-9586-689BC452C4B4

Q36604545-46839DFA-211E-4226-B4EE-D58374CEDE72

P304

Q36604545-BCB0EC01-05CE-4782-83BA-943F884BA3F6

P31

Q36604545-326C10A6-6DCE-4301-A546-6DE52471B1C4

P356

Q36604545-A2EB9714-8772-4933-A69A-DD428D039639

P407

Q36604545-02B35F81-410E-4E33-A5FA-5DE7517ACCAE

P433

Q36604545-D477066C-FD8E-4562-AA42-79D029064231

P478

Q36604545-9E5539C4-6CFE-4973-933A-C419CE2011AE

P577

Q36604545-4D484B27-89A7-4AB8-8C11-F9A896A2F45D

P5875

Q36604545-3FB7E560-233A-49D1-9764-DB79B0649D1B

P698

Q36604545-44DD5B5F-0CEC-4BBF-91E6-90632C1327F1

P921

Q36604545-9CC369F1-C45E-4519-ADEF-B731935DF55D

P932

Q36604545-3CDD33EE-0001-46DB-836A-9387ABC22BE2

P356

PNAS.90.20.9649

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Increased amyloid beta-peptide ...... n late-onset Alzheimer disease

@en

P2093

A D Roses

http://www.w3.org/2001/XMLSchema#string

A M Saunders

http://www.w3.org/2001/XMLSchema#string

B J Crain

http://www.w3.org/2001/XMLSchema#string

C M Hulette

http://www.w3.org/2001/XMLSchema#string

D E Schmechel

http://www.w3.org/2001/XMLSchema#string

D Goldgaber

http://www.w3.org/2001/XMLSchema#string

M A Pericak-Vance

http://www.w3.org/2001/XMLSchema#string

S H Joo

http://www.w3.org/2001/XMLSchema#string

W J Strittmatter

http://www.w3.org/2001/XMLSchema#string

P2860

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene

Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid

Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease

P304

9649-9653

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.90.20.9649

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

1993-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14783065

http://www.w3.org/2001/XMLSchema#string

P698

8415756

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

47627

http://www.w3.org/2001/XMLSchema#string